Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment.

Author: Jialu LV ¹ ; Jianqing LIN ²
Author Information

1. Ningbo University Medical School, Ningbo 315211, China.
2. The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Publication Type:Journal Article
From: Asian Journal of Andrology 2021;23(3):229-230
CountryChina
Language:English